NCT05632809View on ClinicalTrials.gov

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

PHASE2RecruitingINTERVENTIONAL

Enrollment

39

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions

Lung Cancer

Interventions

DRUG

NKTR-255

Given by IV (vein)

DRUG

Durvalumab

Given by IV (vein)

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Nektar Therapeutics

All Listed Sponsors

collaborator

Nektar Therapeutics

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER